Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 15, 2025Zeitschrift für Naturforschung C

Design, synthesis, investigation, and biological activity assessments of n-allyl-2-(benzylidene) hydrazine-1-carbothioamide derivatives as monoamine oxidase-b inhibitor agents

View Full Paper
Ask AI
Bookmark
Share

Authors

SASazan Haji AliDODerya Osmani̇yeBSBegüm Nurpelin Sağlık

Discussion

Loading...

Member takes

Overview

This investigation shows the biological activity of novel MAO-B inhibitors in Parkinson's disease models, suggesting potential therapeutic agents.

Key Points

  • Molecule 3g exhibited the highest inhibitory activity against MAO-B, highlighting its potential as a Parkinson's disease treatment.
  • Biological activity and cytotoxicity assessments included NMR and HRMS spectroscopy as analytical methods.
  • Designing thiosemicarbazone derivatives targeted MAO-B enzyme inhibition, offering new avenues for treatment.
  • Theoretical pharmacokinetic studies indicated favorable drug properties for compound 3g, warranting further exploration.

Cite This Study

Ali et al. (2025) studied this question.

synapsesocial.com/papers/689fc962e46e096235ce1d7ahttps://doi.org/10.1515/znc-2025-0107
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Monoamine Oxidase Inhibitors in Drug Discovery Against Parkinson’s Disease: A Brief Review2025
  2. 2Target-based Virtual Screening of Natural Compounds as Promising Anti-Parkinson’s Agents2025
  3. 3Pharmacophore-Based Virtual Screening of Alkaloids and Flavonoids for Designing Drugs with Inhibitory Activity on the Enzyme Monoamine Oxidase B2025
  4. 4Multi-target monoamine oxidase-B (MAO-B) inhibitors in the treatment of Parkinson’s disease2025
  5. 5Targeting MAO-B selectivity: computational screening, docking, and molecular dynamics insights.2025